| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/25 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Aflatoxin B1 aldehyde reductase member 4, 1---, AFB1 aldehyde reductase 3, AFB1-AR 3, Aldoketoreductase 7-like, AKR7L, AFAR3, AKR7A4 |
| Entrez GeneID | 246181 |
| WB Predicted band size | 37.0kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This AKR7L antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 32-64 amino acids from human AKR7L. |
+ +
以下是关于 **AKR7L (N-Term) 抗体** 的参考文献示例(文献信息为虚构，仅供格式参考)：
---
1. **标题**: *"Characterization of AKR7L Protein Expression in Human Liver Tissue Using a Novel N-Terminal Specific Antibody"*
**作者**: Smith J, et al.
**摘要**: 本研究开发了一种针对AKR7L蛋白N端表位的多克隆抗体，通过Western blot和免疫组化验证了其在人肝组织中的特异性。结果显示AKR7L在肝脏解毒过程中高表达，提示其可能参与外源性代谢调控。
2. **标题**: *"AKR7L Regulates Oxidative Stress Response via Nrf2 Signaling Pathway"*
**作者**: Chen L, et al.
**摘要**: 利用AKR7L (N-Term)抗体，研究者发现AKR7L通过结合Nrf2蛋白增强抗氧化反应元件(ARE)的活性，揭示了其在氧化应激防御中的新机制，为代谢性疾病治疗提供了潜在靶点。
3. **标题**: *"Development and Validation of AKR7L-Specific Antibodies for Functional Studies in Neurodegenerative Models"*
**作者**: García-Ruiz S, et al.
**摘要**: 本文报道了一种高灵敏度的AKR7L N端抗体，成功应用于帕金森病细胞模型中AKR7L的蛋白定位及表达量检测，证实其与神经保护作用相关。
4. **标题**: *"AKR7L Knockout Mice Exhibit Altered Bile Acid Metabolism: Insights from Immunohistochemical Analysis"*
**作者**: Tanaka K, et al.
**摘要**: 通过AKR7L (N-Term)抗体的免疫组化分析，研究发现AKR7L基因敲除小鼠的胆汁酸代谢异常，提示该蛋白在脂溶性毒素清除中的关键作用。
---
**注**：以上文献为示例性质，实际文献需通过PubMed、Google Scholar等平台检索确认。建议使用关键词 **"AKR7L antibody"** 或 **"AKR7A2"**(AKR7L别名)结合 **"N-Term"** 筛选近年研究。
The AKR7L (N-Term) antibody is designed to target the N-terminal region of the aldo-keto reductase family 7 member L (AKR7L) protein, a member of the AKR superfamily involved in detoxification and metabolic pathways. AKR7 enzymes catalyze the NADPH-dependent reduction of harmful aldehydes and ketones, converting them into less reactive alcohols. This family plays a role in cellular defense against oxidative stress, lipid peroxidation products, and xenobiotic toxins. AKR7L shares structural and functional similarities with other AKR7 members (e.g., AKR7A2/AKR7A3) but exhibits distinct tissue expression patterns and substrate preferences. It is implicated in metabolic regulation, particularly in the liver, kidney, and nervous system.
The AKR7L (N-Term) antibody is commonly used in research applications like Western blotting, immunohistochemistry, and immunofluorescence to study AKR7L expression, localization, and function under physiological or pathological conditions. Its specificity for the N-terminal epitope helps differentiate AKR7L from closely related isoforms, minimizing cross-reactivity. Studies utilizing this antibody have explored its role in diseases linked to oxidative stress, such as neurodegenerative disorders, diabetes, and cancer. Researchers also investigate its interaction with cellular pathways involving glutathione metabolism and drug metabolism. Validation typically includes testing reactivity in human, mouse, or rat samples, with attention to molecular weight (~37 kDa) and tissue-specific expression profiles. Proper controls are essential to confirm signal specificity, given the conserved domains within the AKR family.
×
